Company intelligence / Profile preview
neoX Biotech
Beijing, Beijing, Chinaneoxbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
neoX Biotech has demonstrated the power of its AI-driven, protein-protein interaction-based platform through a balanced portfolio of in-house and partnered programs. The company is focused on discovering innovative therapeutics for challenging or 'undruggable' targets, especially in immuno-oncology. No late-stage clinical results have been published as of June 2025.
- Modalities
- Monoclonal antibodyCytokineMacromolecular drugMulti-specific drug
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
I-mab Biopharma (NASDAQ: IMAB)TopAlliance (1877.HK)WuXi BiologicsKactus BiosystemsJohnson & Johnson JLABSMerck Accelerator ProgramMicrosoft AcceleratorAstraZeneca iCampus
Beyond the preview
Go deeper on neoX Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neoX Biotech.